BioCryst Pharmaceuticals (BCRX) Stock Forecast & Price Target

BioCryst Pharma is well positioned by its resilient Orladeyo franchise, which generated $158M in 2Q26 revenue, grew 10% y/y, and helped drive $218M in total revenue and $113M in non-GAAP operating profit, both well ahead of consensus. Its outlook is further strengthened by a growing pediatric pellet rollout with 47 prescriptions already on a YTD basis, plus reiterated FY26 Orladeyo guidance of $625M-$645M and raised FY26 total revenue guidance of $690M-$715M. The company also has meaningful pipeline optionality from navenibart and Netherton syndrome, with a leaner cost structure and $354M in cash/equivalents providing support for continued development and execution.

BioCryst Pharma is viewed negatively because its pipeline remains highly execution-dependent, with regulatory risk, commercial risk, and multiple clinical failure points that could limit approval, label breadth, and market uptake. While deucrictibant showed meaningful efficacy in hereditary angioedema with 45.5% attack-free versus 3.3% on placebo and a 32.2-point AE-QoL improvement at wk-24, safety was not clean, with TEAEs in 76.4% of patients, including Grade 3/4 events, an SAE, and treatment discontinuation. Fundamentally, the company may still need additional external funding, Orladeyo growth could slow or lose share to Takhzyro, CSL Behring, Pharvaris, or Intellia Therapeutics, and even with 2026 non-GAAP opex guidance cut to about $420-440M, the path to >$1B peak sales remains unclear.